Vitamin K2 (MK-7) — Research Profile

Vitamin K1 (phylloquinone) is found in green leafy vegetables and primarily supports blood clotting. Vitamin K2 (menaquinone) is found in fermented foods and animal products and primarily supports calcium metabolism — directing calcium into bones and away from arteries ^[2]. They activate different proteins: K1 mainly activates clotting factors in the liver, while K2 activates osteocalcin (bones) and MGP (arteries) throughout the body.

Yes, combining K2 with vitamin D is recommended, especially at higher D3 doses. Vitamin D increases calcium absorption from the gut, and K2 ensures that calcium goes to your bones rather than accumulating in arteries. Without adequate K2, increased calcium absorption from vitamin D could theoretically contribute to arterial calcification. A general guideline is 100 mcg MK-7 per 1,000-2,000 IU vitamin D3.

MK-7 is generally preferred for daily supplementation because of its long half-life (72 hours) allowing once-daily dosing and consistent blood levels. MK-4 has a very short half-life (1-2 hours) requiring multiple doses daily, but has more direct tissue-level research, particularly for bone health at pharmacological doses (45 mg/day) in Japan. For most people, MK-7 at 100-200 mcg daily is the practical choice.

MK-7 and MK-4 are the two supplemental K2 forms; NIH notes MK-4, MK-7 and MK-9 are the most well-studied menaquinones. NIH reports that MK-7 is well absorbed and has a longer half-life than phytonadione (K1), which supports effective once-daily dosing at microgram amounts, whereas MK-4 has been studied only at much higher pharmacological doses of 15 or 45 mg/day. For once-daily supplementation at microgram doses, MK-7 is the better-characterized choice.

The best-supported benefits come from healthy postmenopausal women: 180 mcg/day of MK-7 for 3 years slowed age-related bone mineral density loss and improved arterial stiffness measures such as carotid-femoral pulse wave velocity. Higher dietary menaquinone intake has been associated with lower coronary heart disease risk in the observational Rotterdam Study, but that is a correlation, not a supplement trial. Evidence outside postmenopausal women, and for actual fracture or cardiovascular event reduction, remains limited.

There is no separate Recommended Dietary Allowance for K2; the vitamin K Adequate Intake is 120 mcg/day for adult men and 90 mcg/day for adult women, figures that reflect total vitamin K and are largely met by K1 from the diet. Clinical MK-7 supplement trials for bone and arterial outcomes used 180 mcg/day. No official dose is set specifically for MK-7, so labels typically supply 90-180 mcg.

Take MK-7 with a meal that contains some fat, since absorption of this fat-soluble vitamin improves with dietary lipids. Its long half-life means blood levels stay relatively steady day to day, so the specific hour matters less than pairing it with food. Time of day has not been directly compared for outcomes in trials.

NIH states vitamin K has not been shown to cause harm, and the 3-year MK-7 trials at 180 mcg/day in postmenopausal women reported no significant adverse effects. There is no established pattern of common side effects at supplemental doses. The meaningful risk is not a side effect but the warfarin interaction described below.

The clinically important interaction is with warfarin (Coumadin) and similar anticoagulants: vitamin K opposes the drug, so a sudden change in intake can cause dangerous bleeding or clotting, and MK-7's long half-life makes even small daily doses persistently influential. Antibiotics, bile acid sequestrants, and orlistat can each lower vitamin K status by reducing gut synthesis or fat absorption. Anyone on warfarin should not start MK-7 without medical supervision and INR monitoring.

People at risk of vitamin K inadequacy are the clearest candidates: those with fat-malabsorption conditions such as cystic fibrosis, celiac disease, ulcerative colitis or short bowel syndrome, and those who have had bariatric surgery. Postmenopausal women concerned about bone loss are the group in whom MK-7 has the most direct supplement evidence. Healthy people with an adequate diet have little demonstrated need, and anyone taking warfarin should avoid starting it without physician guidance.

MK-7 produces no perceptible short-term effect; its actions are on bone and vascular proteins that you cannot feel. Biochemical markers respond within weeks, and the arterial-stiffness trial in postmenopausal women showed dephosphorylated-uncarboxylated matrix Gla protein (a marker of vitamin K status) fall by 50% over the study period. The measurable clinical endpoints, reduced bone loss and reduced carotid-femoral pulse wave velocity, were only demonstrated after 3 years of 180 mcg/day dosing.

The Food and Nutrition Board set no Tolerable Upper Intake Level for vitamin K because of its low potential for toxicity, and NIH reports no adverse effects from vitamin K in food or supplements in humans or animals. The two longest MK-7 trials gave 180 mcg/day for 3 years to healthy postmenopausal women without safety signals. The exception is anyone on warfarin, for whom any vitamin K change can destabilize anticoagulation and requires medical oversight.

No upper limit has been established for vitamin K; NIH states the Food and Nutrition Board declined to set one given its low toxicity, and no adverse effects have been reported from dietary or supplemental intake. This tolerance does not extend to people taking warfarin or similar anticoagulants, in whom excess vitamin K can promote clotting by opposing the drug. Supplemental MK-7 doses in trials were modest (typically 180 mcg/day), so far above-AI intakes have not been formally studied for harm.

As a fat-soluble vitamin, MK-7 is absorbed better when taken with a meal containing some fat. It is commonly paired with vitamin D and calcium on the rationale that vitamin K-dependent proteins (osteocalcin, matrix Gla protein) direct calcium toward bone, but direct trial evidence that the combination outperforms the individual nutrients is limited. There is no known adverse interaction between MK-7 and other vitamins or minerals.

Check that the label states the menaquinone form (MK-7 vs MK-4) and the amount in micrograms, since bone and arterial trials used MK-7 at 180 mcg/day. Menaquinone content and stability can vary between synthetic and natto-derived material, so confirming potency through third-party testing is worth prioritizing. There is no official standardization requirement specific to MK-7, so a clearly stated microgram-per-serving amount plus reputable independent verification are the practical things to look for.